TABLE 3.
Treatment‐emergent adverse events (non‐ocular).
| All grades n (%) | Grade 3–5 a n (%) | |
|---|---|---|
| Thrombocytopenia | 29 (27.4) | 19 (17.9) |
| Infection | 12 (11.3) | 8 (7.5) |
| Anaemia | 12 (11.3) | 4 (3.8) |
| Hypersensitivity/infusion reaction | 8 (7.5) | 3 (2.8) |
| Neutropenia | 8 (7.5) | 5 (4.7) |
| Transaminitis | 5 (4.7) | 1 (0.9) |
| Dry eyes | 5 (4.7) | 0 |
| Fever | 4 (3.8) | 1 (0.9) |
| TLS | 2 (1.9) | 1 (0.9) |
| Cholangitis/elevated bilirubin | 2 (1.9) | 2 (1.9) |
| CMV reactivation | 2 (1.9) | 2 (1.9) |
| AKI | 2 (1.9) | 1 (0.9) |
| Nausea/vomiting | 2 (1.9) | 1 (0.9) |
| Diarrhoea | 2 (1.9) | 1 (0.9) |
| Confusion | 2 (1.9) | 0 |
| Hepatitis B reactivation | 2 (1.9) | 0 |
| Dermatitis | 1 (0.9) | 0 |
| Other b | 11 (10.3) | 6 (5.6) |
Abbreviations: AKI, acute kidney injury; CMV, cytomegalovirus; TLS, tumour lysis syndrome.
a
Two grade 5 adverse events were reported (pneumonia and sepsis).
b
Other adverse effects included (one event each): cough, fatigue, gastritis, general deterioration, gamma glutamyl transferase increase, hypotension, impaired hearing, listeria cerebritis, peripheral neuropathy, pneumonitis, sialadenitis.